Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(28 sites)
United States
Georgia Cancer Center at Augusta University, Augusta, Georgia The University of Chicago Medical Center, Chicago, Illinois Northwestern Memorial Hospital, Warrenville, Illinois Massachusetts General Hospital, Boston, Massachusetts Corewell Health, Grand Rapids, Michigan